Pudafensine - Initiator Pharma
Alternative Names: IP-2015; IP-2017; IPNP-2015; IPTN-2021Latest Information Update: 23 Oct 2023
At a glance
- Originator Initiator Pharma
- Developer Initiator Pharma; MAC Clinical Research; National Institute of Drug Abuse
- Class Analgesics; Drug withdrawal therapies; Erectile dysfunction therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Neurotransmitter uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Erectile dysfunction
- Phase I Neuropathic pain; Trigeminal neuralgia
- Preclinical Pain; Substance-related disorders
Most Recent Events
- 13 Oct 2023 Phase-I clinical trials in Neuropathic pain (unspecified route) before October 2023 (Initiator pharma pipeline, October 2023)
- 18 Jul 2023 Preclinical trials in Neuropathic pain in Denmark (unspecified route) (Initiator Pharma pipeline, July 2023)
- 18 Jul 2023 Initiator Pharma completes enrolment in its phase IIb trial for Erectile dysfunction in UK